Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ANIK
BUYAnika Therapeutics, Inc. · Healthcare · United States · $199M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Anika Therapeutics, Inc. is a global joint preservation company focused on developing and commercializing therapeutic products for pain management, tissue regeneration, and joint repair. Its proprietary hyaluronic acid technology and portfolio of FDA-approved products provide a strong foundation in orthopedic and aesthetic markets. Anika is a niche healthcare company specializing in biomaterial-based solutions for musculoskeletal conditions.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 113.8M | 120.8M | 119.9M | 112.8M | -0.3% | 116.3M | 118.6M | 126.6M | 5.9% |
| EPS | 0.29 | -1.02 | -5.64 | -3.83 | -0.76 | — | -0.78 | — | — | — |
| Shares | — | 14.6M | 14.7M | 14.4M | 13.9M | -5.0% | 13.3M | — | — | — |
| Debt | — | 30.9M | 27.7M | 25.9M | 26.2M | -5.3% | 25.7M | — | — | — |
| Equity | — | 285.6M | 212.3M | 154.0M | 143.5M | -20.5% | — | — | — | — |
| Op CF | — | 4.4M | -1.8M | 5.4M | 11.2M | 36.4% | 6.5M | — | — | — |
| Inv CF | — | -7.5M | -5.4M | -8.3M | -0.4M | — | — | — | — | — |
| Fin CF | — | -4.9M | -6.3M | -12.7M | -10.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ANIK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ANIK | Anika Therapeutics, Inc.(you) | $199M | 76 | BUY |
| SIGA | SIGA Technologies, Inc. | $223M | 76 | BUY |
| EBS | Emergent BioSolutions Inc. | $375M | 80 | STRONG BUY |
| CPIX | Cumberland Pharmaceuticals Inc. | $99M | 68 | BUY |
| CL.CN | Cresco Labs Inc. | $263M | 57 | HOLD |
| AMPH | Amphastar Pharmaceuticals, Inc. | $825M | 75 | BUY |
| PAHC | Phibro Animal Health Corporation | $1.4B | 76 | BUY |
| IRWD | Ironwood Pharmaceuticals, Inc. | $611M | 97 | STRONG BUY |
| TKNO | Alpha Teknova, Inc. | $266M | 36 | HOLD |
| ORGO | Organogenesis Holdings Inc. | $308M | 39 | HOLD |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%